Compare The Travelers Companies Inc. Common Stock (TRV) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
The Travelers Companies Inc. Common Stock vs Travere Therapeutics Inc. Common Stock — how do they compare? The Travelers Companies Inc. Common Stock trades at $382.4 (market cap $78.80B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: The Travelers Companies Inc. Common Stock is far larger — about 15.7× Travere Therapeutics Inc. Common Stock's market cap, and The Travelers Companies Inc. Common Stock pays a 1.32% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold The Travelers Companies Inc. Common Stock for 6 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| TRV | TVTX | |
|---|---|---|
Market Cap | $78.80B | $5.02B |
Volume | 1,311,474 | 2,060,842 |
Sector | Financials | Health |
52-Week High | $397.22 | $67.52 |
52-Week Low | $261.57 | $26.79 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $87.39B | $5.15B |
Dividend Yield | 1.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TRV trades at $373.28, up 0.43% with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with a P/E of 10.03 and ROE of 26.32%, while consistently beating earnings estimates in recent quarters. Recent news highlights Travelers' earnings momentum ahead of Q3 results.
The outlook remains positive given valuation attractiveness and earnings beat history, though risks include competitive pressures and potential earnings volatility. Analyst consensus is mixed with 25% buy ratings but a $353.80 price target below current levels, suggesting cautious optimism.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About The Travelers Companies Inc. Common Stock
The Travelers Companies provides property and casualty insurance for individuals, businesses, and organizations. Its products include auto, home, and commercial coverage.
Read more on TRV →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
